LivaNova PLC (LIVN) Position Cut by HealthCor Management L.P.
HealthCor Management L.P. cut its stake in LivaNova PLC (NASDAQ:LIVN) by 13.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 695,110 shares of the company’s stock after selling 104,890 shares during the period. LivaNova accounts for 2.9% of HealthCor Management L.P.’s portfolio, making the stock its 14th largest position. HealthCor Management L.P. owned approximately 1.43% of LivaNova worth $86,173,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Thrivent Financial for Lutherans increased its stake in LivaNova by 17.0% during the third quarter. Thrivent Financial for Lutherans now owns 11,622 shares of the company’s stock valued at $1,441,000 after purchasing an additional 1,690 shares during the last quarter. Man Group plc increased its stake in LivaNova by 44.7% during the third quarter. Man Group plc now owns 55,537 shares of the company’s stock valued at $6,885,000 after purchasing an additional 17,162 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in LivaNova by 1.1% during the third quarter. The Manufacturers Life Insurance Company now owns 639,937 shares of the company’s stock valued at $79,333,000 after purchasing an additional 7,090 shares during the last quarter. BlueMountain Capital Management LLC bought a new stake in LivaNova during the third quarter valued at $3,171,000. Finally, Paloma Partners Management Co bought a new stake in LivaNova during the third quarter valued at $868,000. 87.53% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have recently commented on the stock. ValuEngine lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 28th. UBS Group assumed coverage on shares of LivaNova in a research report on Tuesday, November 27th. They set a “neutral” rating and a $105.00 price target for the company. BidaskClub lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 22nd. BTIG Research restated a “hold” rating on shares of LivaNova in a research report on Wednesday, November 21st. Finally, Jefferies Financial Group upped their price target on shares of LivaNova to $150.00 and gave the stock a “buy” rating in a research report on Tuesday, October 2nd. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $122.20.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, October 31st. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.08). The firm had revenue of $272.10 million for the quarter, compared to the consensus estimate of $275.03 million. LivaNova had a positive return on equity of 8.77% and a negative net margin of 8.31%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.83 EPS. Equities research analysts predict that LivaNova PLC will post 3.09 EPS for the current year.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $123.49, for a total value of $123,490.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alfred J. Novak sold 500 shares of the stock in a transaction dated Tuesday, December 11th. The shares were sold at an average price of $97.16, for a total transaction of $48,580.00. The disclosure for this sale can be found here. Insiders have sold 9,000 shares of company stock valued at $1,050,935 in the last 90 days. Insiders own 0.41% of the company’s stock.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.